|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
82,823,000 |
Market
Cap: |
1.83(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.92 - $29.92 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 484 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
11,539 |
21,539 |
104,169 |
521,685 |
Total Sell Value |
$248,847 |
$492,446 |
$2,960,641 |
$13,780,081 |
Total People Sold |
2 |
3 |
4 |
7 |
Total Sell Transactions |
2 |
3 |
12 |
30 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kennedy Keith |
COO / CFO |
|
2019-12-02 |
4 |
D |
$27.19 |
$9,245 |
D/D |
(340) |
109,703 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-12-02 |
4 |
D |
$27.19 |
$7,939 |
D/D |
(292) |
47,157 |
|
- |
|
Ho Mark |
Principal Accounting Officer |
|
2019-12-02 |
4 |
D |
$27.19 |
$1,767 |
D/D |
(65) |
21,758 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-11-27 |
4 |
AS |
$29.36 |
$108,534 |
D/D |
(3,697) |
47,449 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-11-27 |
4 |
OE |
$14.34 |
$53,015 |
D/D |
3,697 |
51,146 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-11-18 |
4 |
AS |
$25.18 |
$492,788 |
D/D |
(19,571) |
65,492 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-11-18 |
4 |
OE |
$6.45 |
$126,233 |
D/D |
19,571 |
85,063 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-11-15 |
4 |
AS |
$25.06 |
$501,124 |
D/D |
(20,000) |
103,726 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-11-15 |
4 |
OE |
$4.00 |
$80,000 |
D/D |
20,000 |
123,726 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-10-22 |
4 |
AS |
$27.50 |
$442,729 |
D/D |
(16,091) |
65,492 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-10-22 |
4 |
OE |
$6.45 |
$103,787 |
D/D |
16,091 |
81,583 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-10-22 |
4 |
AS |
$28.00 |
$34,804 |
D/D |
(1,243) |
110,043 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-10-22 |
4 |
OE |
$5.98 |
$7,433 |
D/D |
1,243 |
111,286 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-10-10 |
4 |
AS |
$24.50 |
$196,005 |
D/D |
(8,000) |
103,726 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-10-10 |
4 |
OE |
$2.68 |
$22,546 |
D/D |
7,300 |
111,726 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-09-18 |
4 |
OE |
$7.47 |
$167,067 |
D/D |
22,365 |
110,043 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-09-16 |
4 |
AS |
$25.66 |
$477,089 |
D/D |
(18,593) |
65,492 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-09-16 |
4 |
OE |
$5.98 |
$111,186 |
D/D |
18,593 |
84,085 |
|
- |
|
Anderson Bonnie H |
Chairman and CEO |
|
2019-09-10 |
4 |
AS |
$23.27 |
$196,114 |
D/D |
(8,000) |
104,426 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-09-04 |
4 |
AS |
$25.20 |
$7,458 |
D/D |
(296) |
47,449 |
|
- |
|
Kennedy Keith |
COO / CFO |
|
2019-09-03 |
4 |
D |
$25.09 |
$8,531 |
D/D |
(340) |
87,678 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-09-03 |
4 |
D |
$25.09 |
$7,326 |
D/D |
(292) |
47,745 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-09-03 |
4 |
AS |
$25.20 |
$380,656 |
D/D |
(15,031) |
48,037 |
|
- |
|
Kennedy Giulia C |
Chief Scientific & Med Officer |
|
2019-09-03 |
4 |
OE |
$5.43 |
$107,100 |
D/D |
15,031 |
63,068 |
|
- |
|
Hanna John Walter Jr |
Chief Commercial Officer |
|
2019-09-03 |
4 |
D |
$25.09 |
$3,814 |
D/D |
(152) |
65,492 |
|
- |
|
524 Records found
|
|
Page 14 of 21 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|